T1	intervention 117 126	tamoxifen
T2	total-participants 294 298	4128
T3	eligibility 299 434	postmenopausal patients with early stage breast cancer who were alive and free of breast cancer recurrence after two years of tamoxifen
T4	outcome 571 611	incidence of contralateral breast cancer
T5	outcome 913 944	incidence of endometrial cancer
T8	outcome 662 673	lung cancer
